Dr. Alhalabi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161
Summary
- Dr. Omar Alhalabi, based in Houston, Texas, specializes in Oncology. He received his medical degree from Damascus University Faculty of Medicine in 2013, completed his residency in Internal Medicine at Beaumont Health (Royal Oak) from 2014-2017, and pursued a fellowship in Hematology and Medical Oncology at the University of Texas Health Science Center at Houston/M D Anderson Cancer Center from 2017-2020. He has publications in various reputed journals including The Oncologist, the Journal of Urology, the European Urology Oncology, and Journal of Clinical Oncology. Additionally, Dr. Alhalabi is involved in clinical trials, including a Phase 2 study evaluating the triplet combination of Pemetrexed Plus AB928 + AB122 in patients with advanced or metastatic MTAP Deficient Urothelial Carcinoma, and a Phase 1a/b study of IK-175 combined with Nivolumab in patients with Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma.
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2017 - 2020
Corewell Health East Beaumont (Royal Oak)Residency, Internal Medicine, 2014 - 2017
Damascus University Faculty of MedicineClass of 2013, MD
Certifications & Licensure
FL State Medical License 2021 - Present
MI State Medical License 2014 - 2026
WA State Medical License 2023 - 2026
AZ State Medical License 2023 - 2025
GA State Medical License 2023 - 2025
LA State Medical License 2023 - 2025
MS State Medical License 2023 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
- Join now to see all
Clinical Trials
- A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma Start of enrollment: 2023 Jun 13
- A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma Start of enrollment: 2019 Dec 18
Publications & Presentations
PubMed
- 189 citationsNeoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma.Jianjun Gao, Neema Navai, Omar Alhalabi, Arlene O. Siefker-Radtke, Matthew T. Campbell
Nature Medicine. 2020-10-12 - 86 citations9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy.Guangchun Han, Guoliang Yang, Dapeng Hao, Yang Lu, Kyaw Zin Thein
Nature Communications. 2021-09-23 - 2 citationsPhase 1b Trial Evaluating Tolerability and Activity of Targeted Fibroblast Growth Factor Receptor Inhibition in Localized Upper Tract Urothelial Carcinoma.Surena F Matin, Mehrad Adibi, Amishi Y Shah, Omar Alhalabi, Paul Corn
The Journal of Urology. 2024-06-01
Press Mentions
Metastatic Prostate Cancer: Investigators Ponder New Path to Improve SurvivalSeptember 30th, 2022- Noncancer Causes of Death ‘Increasingly Pertinent’ Among Men with Advanced Prostate CancerOctober 29th, 2021
- Old Saying About Prostate Cancer Not True When It’s MetastaticSeptember 7th, 2021
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
